Anzeige
Meldung des Tages: Auftakt zu Maßnahmen: Grundlegendes Material für die Verteidigungsindustrie der USA wird immer wichtiger

Ideaya Bioscience Aktie News

Aktie
WKN:  A2PJPB ISIN:  US45166A1025 US-Symbol:  IDYA Branche:  Biotechnologie Land:  USA
26,80 €
-0,4 €
-1,47%
08:46:38 Uhr
Depot/Watchlist
Marktkapitalisierung *
2,62 Mrd. €
Streubesitz
-
KGV
-28,46
neu: Nachhaltigkeits-Score
22 %
Index-Zuordnung
-

Ideaya Bioscience News

06:00 Uhr - PR Newswire
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events PR Newswire
30.01.26 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
11.01.26 - PR Newswire
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
05.01.26 - PR Newswire
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
11.12.25 - PR Newswire
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-​line HLA*A2-...
10.12.25 - PR Newswire
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-​In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers PR Newswire
01.12.25 - PR Newswire
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-​in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types PR Newswire
28.11.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.11.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events PR Newswire
04.11.25 - PR Newswire
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
31.10.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
27.10.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events PR Newswire
20.10.25 - PR Newswire
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 ...
20.10.25 - PR Newswire
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-​line Metastatic Uveal Melanoma at the ...
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
26.09.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire
08.09.25 - PR Newswire
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-​in-class MAT2A inhibitor, and Trodelvy® in MTAP-​Deletion Urothelial ...

Newssuche

Videos

newspaper
12:40 Uhr 0,00%
Technical Trading Silber Crash!
Silber Short Typ: Turbo Open End WKN: VJ4GQU Hebel: 3,77 Laufzeit: OpenEnd Einstieg: Market ... Mehr »